Addiction Toxicology Case Conference - December 2024
-
Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
Abuse of Performance Enhancing Agents, Weight Loss (Semaglutide)
Cases
1. Athlete Using Online Anabolic and Growth Hormone Releasing Peptides
2. Performance Enhancing GLP-1s: Altering Appearance with Counterfeit Semaglutide
Learning Objectives
1. List 3 performance-enhancing agents available through online and other sources commonly misused by athletes.
2. Evaluate the impact of counterfeit GLP-1 agonists, including semaglutide, on performance enhancement and weight loss, and examine strategies for healthcare professionals to identify and mitigate the risks associated with their misuse.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is open to the public.
Continuing Education credits are now available for this activity! Click here for more info.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults
University of Rochester Medical Center
Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). In 2023, he began a two-year term as Treasurer of ASAM, having previously served as Vice President on the Executive Council. Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Michael B. Marlin, MD
Assistant Professor, School of Medicine, Department of Emergency Medicine
University of Mississippi Medical Center
Dr. Marlin grew up in Tupelo, Mississippi, and graduated from Tupelo High School in 2003. He attended Mississippi State University where he ran cross country and track & field. Michael graduated from MSU in 2007 with a Bachelor of Science in Microbiology. He completed his medical school training and his emergency medicine residency at the University of Mississippi Medical Center. Michael completed his medical toxicology fellowship at the Rocky Mountain Poison and Drug Safety in Denver, Colorado in 2017. He is board-certified in emergency medicine, medical toxicology, and addiction medicine.
Dr. Marlin has financial relationships with Novo Nordisk and Eli Lilly, manufacturers of GLP-1 agonists approved for glycemic control in diabetes and obesity management.
Stephanie Weiss, MD, PhD
Staff Clinician, Translational Addiction Medicine Branch
National Institute on Drug Abuse
Dr. Stephanie Weiss is the Staff Research Physician serving the Translational Addiction Medicine Branch of the National Institute on Drug Abuse’s Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree in 2011. She is board certified in emergency medicine, addiction medicine, and medical toxicology and was selected to participate in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss is responsible for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission conducting inpatient and outpatient proof-of-concept human laboratory studies. Her research interests include novel psychoactive substances, medication misuse, and improving interpretation of urine drug testing.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.
Nurses
Credit being awarded: 1.25 ANCC contact hours.
Athletic Trainers
AKH Inc., Advancing Knowledge in Healthcare (BOC AP#: JA0007034) is approved by the Board of Certification, Inc. to provide continuing education to Athletic Trainers (ATs). This program is eligible for a maximum of 1.25 Category A hours/CEUs. ATs should claim only those hours actually spent in the educational program
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Michael Marlin, MD, Faculty: has nothing to disclose
Stephanie Weiss, MD, PhD, Faculty: has nothing to disclose
Stephen Taylor, MD, MPH, Faculty: has nothing to disclose
AKH Planners and Reviewers: have nothing to disclose.
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
Key:
Complete
Next
Failed
Available
Locked